TRVI highs up around 12%, benefiting from GSK stopping its Chronic cough study
TRVI highs up around 12%, benefiting from GSK stopping its Chronic cough study
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.